OR
CLICK HERE TO REGISTER AT NO COST
SAVE 20% - 50% ON
Medical Supplies
You are not eligible to purchase this product. Please contact your account manager for more information.
Additional Information
Description
Ibrance (palbociclib) 75 mg is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor used for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It works by selectively inhibiting CDK4 and CDK6, which regulate cell cycle progression. By blocking these kinases, Ibrance prevents cancer cell proliferation, inducing cell cycle arrest at the G1 phase.
The medication is supplied in 75 mg capsules, with each package containing 21 capsules. It is taken orally once daily for 21 consecutive days, followed by a 7-day treatment-free interval in a 28-day cycle. Ibrance is typically used in combination with an aromatase inhibitor or fulvestrant, depending on the patient's treatment history and menopausal status.
Common adverse effects include neutropenia, fatigue, nausea, stomatitis, diarrhea, and infections. Serious complications such as severe neutropenia, pulmonary toxicity, and venous thromboembolism may occur. Regular blood count monitoring is necessary to detect and manage neutropenia.
You've just added this product to thecart: